Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- The FDA has declared semaglutide and tirzepatide shortages resolved, which ended mass compounding of GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.
- Compounding pharmacies may only produce patient-specific GLP-1 versions under narrow 503A exceptions when a documented clinical need exists, such as an allergy to an inactive ingredient.
- Compounded GLP-1s carry elevated safety risks including dosing errors, contamination, and potency variability, with over 1,700 adverse event reports logged by the FDA as of May 2026.
- Patients should verify pharmacy credentials including state licensure, PCAB accreditation, 503A/503B status, and batch-specific Certificates of Analysis before accepting any prescription.
- Book a consultation to discuss your GLP-1 or GLP-3R options at Mirror Plastic Surgery and review a medically supervised protocol tailored to your health profile.
Current Rules for Compounding Pharmacies and GLP-1
Compounding pharmacies can still dispense GLP-1 medications, but only in narrow, patient-specific situations. Since the FDA resolved the semaglutide shortage on February 21, 2025, and the tirzepatide shortage in October 2024, pharmacies can no longer mass-produce copies of these drugs. Under section 503A of the FD&C Act, a pharmacy may compound a patient-specific version only when a prescriber documents a clinical need the approved drug cannot meet, such as an allergy to an inactive ingredient. Compounding for cost, convenience, or preference is not permitted.
The FDA’s Crackdown on Mass GLP-1 Compounding
The FDA followed a clear regulatory timeline. The agency removed tirzepatide from its shortage list in October 2024 and semaglutide on February 21, 2025. This change triggered staged deadlines. 503A pharmacies had to stop compounding tirzepatide by mid-February 2025 and semaglutide by April 22, 2025. 503B outsourcing facilities faced deadlines of March 19, 2025, and May 22, 2025, respectively.
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This proposal closed a major pathway for large-scale compounding. FDA Commissioner Marty Makary stated, “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.”
Enforcement has been active. The FDA issued more than 55 warning letters to telehealth companies and compounders in September 2025, followed by 30 more in March 2026 and 25 in June 2026. These actions targeted misleading claims that compounded products are “the same as” FDA-approved drugs. The compounding industry’s trade group sued the FDA twice over the shortage delistings, and the Fifth Circuit affirmed the FDA’s decisions in August and September 2026.
Compounded GLP-1 Safety: What the Data Shows
As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 for compounded tirzepatide. A 2026 pharmacovigilance study in Expert Opinion on Drug Safety analyzed FAERS data. It found that compounded GLP-1s had significantly higher reporting odds for preparation errors (ROR 48.92), contamination (19.00), and hospitalization (2.35) compared to non-compounded products.
A 2024 JAMA Network Open study found 68% of peptide products from online vendors did not contain the labeled amount of active ingredient. Some products contained bacterial endotoxins above acceptable limits and undisclosed additives. Similarly, America’s Poison Centers reported managing 22,966 GLP-1 agonist exposure cases from 2019 through 2025, with compounded products linked to 10-fold dosing mistakes caused by syringe measurement confusion.
Most risk concentrates in unregulated or low-quality sources. The peptide molecules themselves have well-established safety profiles in large clinical trials. The Obesity Society’s March 2026 statement acknowledges compounding’s appropriate role for individual patient needs. It also warns against mass-market production and the addition of vitamins and minerals “under the guise of personalization,” which it calls “not only a sham, but may have harmful effects.”
For a deeper review of compounded semaglutide specifically, see Mirror Plastic Surgery’s guide on Compounded Semaglutide Safety: Risks & How to Stay Safe.
Discuss Your GLP-1 Options With Dr. Chandawarkar and review whether a medically supervised protocol fits your health profile.
How to Verify a Legitimate Compounding Pharmacy
Patients can protect themselves by checking a few key details before filling any compounded GLP-1 prescription. This step-by-step checklist helps separate quality-driven pharmacies from gray-market sources.
- Confirm state board of pharmacy licensure. Check your state board’s online license lookup tool. Verify that the license is active, matches the pharmacy’s published name, and shows no recent disciplinary actions.
- Determine 503A vs. 503B status. 503A pharmacies compound patient-specific prescriptions under state oversight, while 503B outsourcing facilities register with the FDA, undergo routine inspections, and must follow current Good Manufacturing Practice (cGMP) standards.
- Verify PCAB accreditation. Fewer than 1% of U.S. compounding pharmacies hold Pharmacy Compounding Accreditation Board accreditation. This accreditation requires independent on-site audits and demonstrated compliance with USP <797> sterile compounding standards.
- Request a batch-specific Certificate of Analysis (CoA). A legitimate pharmacy will provide third-party lab results confirming potency (90–110% of labeled strength) and sterility for the specific batch you receive.
- Confirm the active ingredient is the base form. The FDA states semaglutide sodium and semaglutide acetate are “different active ingredients” from the approved base form, and the agency is “not aware of any lawful basis for their use in compounding.”
- Require a valid prescription from a licensed provider. NABP found that 96% of illegal online pharmacies do not require a prescription. Any pharmacy that sells without one operates outside the law.
Compounded GLP-1 vs. Brand-Name Medications
Brand-name GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved and manufactured under strict quality controls. They are backed by extensive clinical trial data, including cardiovascular outcomes studies. The cardiovascular benefits documented in the SELECT, SOUL, and SUSTAIN trials are based on branded semaglutide. Manufacturing variability in compounded versions means those benefits cannot be directly extrapolated.
Compounded versions have historically offered cost advantages, although that gap has narrowed. Novo Nordisk dropped the self-pay price of Wegovy and Ozempic to $349 per month in November 2025. Brand-name options have also expanded. Oral Wegovy launched in early 2026, and Eli Lilly’s oral Foundayo was approved April 1, 2026. Dosing flexibility and specific excipient needs may still make patient-specific compounding appropriate in narrow cases. A physician should evaluate those scenarios.
For a broader comparison of GLP-1 safety considerations, see Mirror Plastic Surgery’s article on GLP-1 Peptide Safety: Risks and Benefits Explained.
Questions to Ask Before Starting GLP-1 Therapy
A qualified physician should address several core topics before any GLP-1 protocol begins. If a provider cannot or will not engage with these points, consider that a red flag.
- Whether compounded GLP-1 is appropriate for your medical history, or whether an FDA-approved option would be safer
- Which baseline lab tests you need before starting, such as A1C, lipid panel, comprehensive metabolic panel, and TSH
- Which pharmacy will fill your prescription, and whether its 503A/503B status and PCAB accreditation can be verified
- The exact concentration and dose in both milligrams and syringe units
- How your progress will be monitored and what follow-up schedule you should expect
- Which side effects require immediate medical attention
- The plan if you need to stop treatment or if your supply is interrupted
Mirror Plastic Surgery’s guide on GLP-1 Lab Monitoring: What Blood Tests You Need covers the specific panels Dr. Akash Chandawarkar reviews before and during peptide therapy.
Alternatives to Compounded GLP-1s
FDA-approved injectable and oral GLP-1 medications remain the most straightforward legal pathway for most patients in 2026. For patients whose needs are not met by standard formulations, or who are interested in next-generation options, Mirror Plastic Surgery also offers GLP-3R compounding. This newer-generation peptide is reported to have fewer gastrointestinal side effects than older GLP-1 versions, and it may also be less likely to cause muscle wasting.1 Its potential indications are broader, including insulin resistance, weight management, and cardiovascular risk factors. Dr. Akash Chandawarkar evaluates each patient’s labs and health profile to determine which protocol is most appropriate.
Schedule a Consultation to Explore GLP-3R and Other Peptide Options and align your treatment plan with your goals.
Meet the Expert: Dr. Akash Chandawarkar
Dr. Akash Chandawarkar, MD, is the founder of Mirror Plastic Surgery and the lead physician for all peptide therapy protocols at the practice. He is board-certified by the American Board of Plastic Surgery and graduated with Honors from Harvard Medical School through the Harvard-MIT Division of Health Sciences and Technology. His clinical training includes a seven-year integrated plastic and reconstructive surgery residency at Johns Hopkins University, fellowship training in aesthetic surgery at the Manhattan Eye Ear & Throat Hospital/Lenox Hill Hospital, and the Stanford University Biodesign Innovation Fellowship, a program that trains physician-innovators to identify unmet clinical needs and develop technological solutions.
Dr. Akash’s approach to peptide therapy follows the same philosophy that guides his surgical practice: safety first, function second, aesthetics third. Every peptide protocol is designed around the patient’s labs and physiology, medically supervised throughout, and supported by direct access via text for ongoing questions. Consultations typically run up to an hour and cover medical history, lab review, and a transparent discussion of what each peptide can and cannot do. He often advises patients to delay or avoid therapy when it is not yet necessary, prioritizing long-term outcomes over short-term revenue.
For patients in the Tampa Bay and St. Petersburg area, as well as those seeking remote care across the United States, Mirror Plastic Surgery offers the full consultation-to-prescription process in person or via telemedicine. See how Mirror Plastic Surgery compares to other providers in the Medical Grade GLP-1 Peptide Providers in Florida guide.
Conclusion: Making an Informed Decision
The legal status of compounded GLP-1s is now restrictive, and safety depends heavily on sourcing and supervision. The FDA’s resolution of GLP-1 shortages ended the era of mass-produced compounded semaglutide and tirzepatide. Patient-specific compounding under 503A remains a narrow but legal pathway for documented clinical need, and it requires a qualified prescriber, a verified pharmacy, and ongoing medical oversight to be done safely.
The decision to pursue any GLP-1 or peptide protocol works best as a collaborative process with a physician who reviews your labs, evaluates your medical history, and builds a plan around your specific goals. At Mirror Plastic Surgery, Dr. Akash Chandawarkar brings board-certified medical expertise, Harvard and Johns Hopkins training, and a concierge approach to every peptide consultation.
Start Your Personalized, Medically Supervised Peptide Plan and move forward with clarity about your GLP-1 and GLP-3R options.
Disclaimer: Compounded GLP-1 medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Results vary among individuals. Professional medical supervision is strongly recommended before starting any peptide therapy.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
